Carsten Utoft Niemann

Carsten Utoft Niemann

Auto-generated profile, based on publicly available information

Carsten Utoft Niemann

Rigshospitalet, Copenhagen Ø, Denmark

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CEChristian Winther Eskelund
Christian Winther Eskelund
CDChristina Dahl
Christina Dahl
JHJakob W. Hansen
Jakob W. Hansen
MWMaj Westman
Maj Westman
AKArne Kolstad
Arne Kolstad
KGKirsten Grønbæk
Kirsten Grønbæk
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable and we are still unable to identify patients who will not benefit from the current standard-of-care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger MCL patients from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53 (11%) and NOTCH1 (4%), and deletions of TP53 (16%) and CDKN2A (20%) were significantly associated with inferior outcomes (together with MIPI, MIPI-c, Blastoid morphology and Ki67>30%); however, in multivariate analyses only TP53 mutations (HR=6.2, p<0.0001) retained prognostic impact for overall survival (OS), while TP53 mutations (HR=6.9, p<0.0001) and MIPI-c high-risk (HR=2.6, p=0.003) had independent prognostic impact on time to relapse. TP53-mutated cases had a dismal outcome with a median OS of 1.8 years and 50% relapsed at 1.0 years (compared to not reached (NR) and 12.7 years, respectively, for TP53-unmutated cases, p30%, blastoid morphology, MIPI high-risk and inferior responses to both induction- and high-dose chemotherapy. In conclusion, we show that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to regimens including cytarabine, rituximab and autologous stem-cell transplant (ASCT). We suggest that MCL patients should be stratified according to TP53 status, and that patients with TP53 mutations should be considered for experimental frontline trials exploring novel agents. Key points The intensified standard-of-care regimens for younger MCL patients do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.

1 February 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
MFMohammed Z H Farooqui
Mohammed Z H Farooqui
JVJanet Valdez
Janet Valdez
SMSabrina Martyr
Sabrina Martyr
GAGeorg Aue
Georg Aue
NSNakhle Saba
Nakhle Saba
AWAdrian Wiestner
Adrian Wiestner

9 July 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
LSLydia Scarfò
Lydia Scarfò
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
GRGian Matteo Rigolin
Gian Matteo Rigolin
GQGiulia Quaresmini
Giulia Quaresmini
MMMarina Motta
Marina Motta
PGPaolo Prospero Ghia
Paolo Prospero Ghia

17 January 2018 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
ARAndy C. Rawstron
Andy C. Rawstron
KKKarl‐Anton Kreuzer
Karl‐Anton Kreuzer
ASAsha Soosapilla
Asha Soosapilla
MSMartin Spacek
Martin Spacek
OSOlga Stehlikova
Olga Stehlikova
EMEmili Montserrat
Emili Montserrat
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as “required” or “recommended” for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate “required” markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5–20 in 82/150 (55%), and 97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as “required” for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus “recommended” panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. © 2017 International Clinical Cytometry Society

31 March 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CNCarsten U. Niemann
Carsten U. Niemann
SHSarah E.M. Herman
Sarah E.M. Herman
IMIrina Maric
Irina Maric
JGJulio Gomez-Rodriguez
Julio Gomez-Rodriguez
ABAngelique Biancotto
Angelique Biancotto
AWAdrian Wiestner
Adrian Wiestner
Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor cells from the microenvironment. Although the on-target effects on CLL cells are well defined, the impact on the microenvironment is less well studied. We therefore sought to characterize the in vivo effects of ibrutinib on the tumor microenvironment. Experimental Design: Patients received single-agent ibrutinib on an investigator-initiated phase II trial. Serial blood and tissue samples were collected pretreatment and during treatment. Changes in cytokine levels, cellular subsets, and microenvironmental interactions were assessed. Results: Serum levels of key chemokines and inflammatory cytokines decreased significantly in patients on ibrutinib. Furthermore, ibrutinib treatment decreased circulating tumor cells and overall T-cell numbers. Most notably, a reduced frequency of the Th17 subset of CD4+ T cells was observed concurrent with reduced expression of activation markers and PD-1 on T cells. Consistent with direct inhibition of T cells, ibrutinib inhibited Th17 differentiation of murine CD4+ T cells in vitro. Finally, in the bone marrow microenvironment, we found that ibrutinib disaggregated the interactions of macrophages and CLL cells, inhibited secretion of CXCL13, and decreased the chemoattraction of CLL cells. Conclusions: In conjunction with inhibition of BCR signaling, these changes in the tumor microenvironment likely contribute to the antitumor activity of ibrutinib and may impact the efficacy of immunotherapeutic strategies in patients with CLL. Clin Cancer Res; 22(7); 1572–82. ©2015 AACR. See related commentary by Bachireddy and Wu, p. 1547

1 December 2013 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
CNCarsten U. Niemann
Carsten U. Niemann
AWAdrian Wiestner
Adrian Wiestner